PALACE-DUBAI-CREEK
Palace Dubai Creek Harbour Hotel by Emaar Hospitality Group has officially opened its doors in the centre of Dubai, presenting a blend of contemporary elegance and Arabian allure. With its premium waterside position on the Dubai Creek shoreline, the hotel boasts magnificent, unrestricted waterfront views and offers a refreshing take on the Dubai skyline. To celebrate the opening, special offers have been extended from May 1st to May 31st, 2024, including a 30% discount on the Best Available Rates and complimentary breakfast.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430488407/en/
Palace Dubai Creek Harbour Hotel Officially Opens Its Doors in the Heart of Dubai (Photo: AETOSWire)
Nestled within Dubai Creek Harbour, an avant-garde waterfront district, Palace Dubai Creek Harbour provides guests with access to expansive parks, cultural spaces, and pedestrian-friendly streets, epitomising the zenith of modern urban planning. The hotel is conveniently located a 15-minute drive from Dubai International Airport, and it is also in close proximity to iconic landmarks such as Dubai Mall, Burj Khalifa, and downtown attractions. Connected to a major bridge, it blends convenience with serenity, perfect for travellers seeking both accessibility and peace.
The hotel’s enviable amenities include a striking rooftop infinity pool, spa services, and guest rooms with generous private balconies. Boasting 122 rooms, offering various options including suites, that are decked out with top-of-the-line furnishings and design details that evoke modern Arabian sophistication. The hotel’s interiors reflect opulent Arabesque décor, showcasing a synergy of heritage art pieces with contemporary architecture.
Palace Dubai Creek Harbour also offers an enticing dining experience at Fai Lounge, which offers a poolside vibe during the day and transforms into a chic evening venue. Guests can take pleasure in Levantine and Arabian flavors at familiar restaurants such as Ewaan and Al Bayt. These dining venues, complete with sumptuous indoor spaces and open-air terraces, aim to be the go-to destination throughout the year.
Designed for both leisure and business travellers, the property boasts a fully equipped 24/7 fitness centre, a vibrant Qix Club for kids, a Boardroom and a Business Centre. The spa offers a serene sanctuary, providing rejuvenating treatments for guests.
Palace Dubai Creek Harbour champions a luxurious experience that melds classical refinement with the latest in opulence, ensuring guests enjoy panoramic vistas of the city and the canal.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430488407/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom